For the CSS, TSS, and OSS, the Emax of the SGLT-2 inhibitors on the quality of life in HF patients is 3.74%, 4.43%, and 4.84%, respectively, and the ET50 is 2.23, 4.37, and 7.15 weeks, respectively. Here, SLC5A2 is linked to hydrops fetalis.